Inhibitex Inc. joined the ranks of private biotech companies looking to take advantage of a more receptive market with an initial public offering filing aimed at raising $86.25 million. (BioWorld Today)

Recurrent respiratory papillomatosis represents the first indication that Stressgen Biotechnologies Corp. intends to pursue with its drug HspE7, based on positive Phase II data released this week. (BioWorld Today)